|Articles|June 6, 2013
From ASCO: Updates in HER2-positive breast cancers
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Darzalex Faspro in High-Risk Smoldering Multiple Myeloma
2
Top Lung Cancer Stories from October: Insights, and Patient Journeys
3
October Treatment Advances and Survivorship Perspectives in GU Cancers
4
Myeloma Advocate Stresses Support for Caregivers in Black Community
5
